RecruitingNCT05117424
CArdioMetabolism and Atherosclerotic PlaqUe progreSsion
The Impact of Cardiometabolic Factors on Coronary Artery and Cardiovascular Diseases: a Prospective Cohort Study
Sponsor
Ruijin Hospital
Enrollment
3,000 participants
Start Date
Jan 1, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
Systematic metabolic diseases are closely related to prevalence and progression of atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery disease compliacted with metabolic abnormalities such as diabtetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria9
- Age 18-80 years
- Established coronary artery disease or metabolic disorders, including:
- Type 2 diabetes diagnosed by one of the following criteria:
- HbA1c \>/= 6.5% Fasting plasma glucose \>/= 7.0 mmol/l (confirmed) 2h plasma glucose value during OGTT \>/= 11.1 mmol/l Already receiving glucose-lowering agents
- Prediabetes
- Obesity
- Chronic kidney disease
- Hyperuricemia
- Dyslipidemia
Exclusion Criteria7
- Severe liver failure (Child-Pugh grade B to C)
- Severe anemia (hemoglobin \< 60g/L)
- Familial hypercholesterolemia
- Active malignant tumor
- Active autoimmune diseases on corticosteroids
- Acute or chronic infection
- Life expectancy \< 1 year
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05117424
Related Trials
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
NCT0724708425 locations
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418115 locations
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
NCT070107571 location
Development of Novel Physiological CMR Methods in Health and Disease
NCT038540711 location